Molecular diagnostics company Cepheid reported on Tuesday the receipt of US Food & Drug Administration (FDA) Emergency Use Authorization (EUA) for Xpert Xpress CoV-2/Flu/RSV plus, for the qualitative detection of the viruses causing COVID-19, Flu A, Flu B and respiratory syncytial virus (RSV) infections from a single patient sample.
The company said the new plus version of the diagnostics test provides a third gene target for SARS-CoV-2 detection to meet the challenge of future viral mutations. Multiple variants of the virus that causes COVID-19 have been documented globally during the pandemic.
According to the company, the Xpert Xpress CoV-2/Flu/RSV plus is designed for use on any of its over 35,000 GeneXpert Systems placed worldwide, with results delivered in approximately 36 minutes.
In addition, the company's Xpert Xpress CoV-2/Flu/RSV plus is expected to begin shipping to US customers in the next few weeks.
Viruses constantly change through mutation, and new variants of a virus are expected to occur over time. Adding a 3rd gene target to the plus version of the company's CoV-2/Flu/RSV test delivers broader coverage to mitigate the possible effects of future viral genetic drift.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review